Icure Pharmaceutical Incorporation (175250) — Cash Flow Quality Index

Latest as of December 2024: -689.55x

Icure Pharmaceutical Incorporation (175250) has a Cash Flow Quality Index of -689.55x as of December 2024. Operating cash flow of ₩-17.05 Billion is below net income of ₩24.73 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 175250 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-689.55x
Operating CF / Net Income

Operating Cash Flow

₩-17.05 Billion
KRW

Net Income

₩24.73 Million
KRW

Data as of

Dec 2024
Most recent filing

Icure Pharmaceutical Incorporation Cash Flow Quality Index (2017–2024)

Historical Cash Flow Quality Index for Icure Pharmaceutical Incorporation across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 175250 operating cash flow.

Annual Cash Flow Quality Index for Icure Pharmaceutical Incorporation (2017–2024)

Year-by-year earnings quality comparison for Icure Pharmaceutical Incorporation.

Year Quality Index Operating CF (KRW) Net Income YoY Change
2024 -689.55x ₩-17.05 Billion ₩24.73 Million ▼ -33240.2%
2017 2.08x ₩1.12 Billion ₩537.95 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.